KOSPIHolding Companies005250

GC

₩9,220▼ 2.43%2026-11-18 close
Market Cap
₩433.6B
Turnover
₩500M
Volume
50K
Shares out.
47M
PER
—
PBR
0.5×
EPS
-₩949
Dividend Yield
3.19%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩300 per share · Prices as of the 2026-11-18 close

01

Report overview

Operating Recovery Continues, Net Losses Linger at the Holding Level

GC Holdings returned to operating profit in 2025 and posted KRW 60 billion in operating profit in Q3 2026, but cumulative net losses of KRW 47 billion over the last four quarters and a higher debt ratio remain open issues.

  1. 1

    Operating profit in Q3 2026 was KRW 60 billion, up 130.4% from the year-earlier quarter, and profit attributable to controlling shareholders reached KRW 84.3 billion.

  2. 2

    Operating profit turned positive to KRW 36.2 billion in 2025, while net loss attributable to controlling shareholders widened to KRW 69.5 billion, so the two measures moved in opposite directions.

  3. 3

    Net loss attributable to controlling shareholders totaled 47 billion won over the last four quarters, so a price-to-earnings ratio cannot be calculated on that basis.

  4. 4

    The debt ratio rose to 130.7% at the end of 2025 from 82.6% in 2022, and controlling shareholders' equity of KRW 900.9 billion is about half of total equity of KRW 1.76 trillion.

  5. 5

    An upfront payment of KRW 46.8 billion from a Fabry disease therapy licensing deal at subsidiary GC Biopharma is scheduled to be recognized in Q4 2026 results.

02

Business structure

GC Holdings was restructured as a pure holding company in 2001 and does not manufacture products directly. The holding company sets group strategy, pursues new business entries and manages its investment portfolio, while subsidiaries conduct actual pharmaceutical manufacturing and sales.

As of the 2026 annual report, the group had 54 affiliates, with 33 in Korea and 21 overseas. Its core subsidiary GC Biopharma, in which the holding company owns 50.06%, handles plasma-derived products and vaccines. ALYGLO, an immunoglobulin product, and flu vaccines are cited as its main product lines.

Other subsidiaries cover diagnostic reagents and medical devices, health functional foods and raw materials, cell therapy and genome analysis. In the United States, ABO Holdings operates plasma collection centers under GC Biopharma, and collection center utilization drives the profitability of that business.

The pharmaceutical manufacturing and sales segment is the largest part of the group. Domestic vaccine sales concentrate in the flu season, which makes quarterly results seasonal.

Holding-level results combine consolidated subsidiary performance with equity-method and disposal gains, so sales trends and net profit trends should be read separately.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩736.9B₩26B3.5%
2025Q4₩619.5B-₩6.7B−1.1%
2026Q1₩534.8B₩3.1B0.6%
2026Q2₩596.3B₩6.6B1.1%
2026Q3₩702.3B₩60B8.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩2.1T₩71.2B₩32.8B3.4%3.2%82.6%
2023₩2.1T-₩16.4B-₩54.1B−0.8%−5.5%98.7%
2024₩2.2T-₩10.7B₩24B−0.5%2.4%98.2%
2025₩2.5T₩36.2B-₩69.5B1.5%−7.7%130.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual sales fell 1.0% to KRW 2.08 trillion in 2022 to KRW 2.06 trillion in 2023. Sales then rose 7.1% to KRW 2.2 trillion in 2024 and 11.2% to KRW 2.45 trillion in 2025, and 2025 was the largest year in the 2022 to 2025 period.

Operating profit moved from KRW 71.2 billion in 2022 to an operating loss of KRW 16.4 billion in 2023, which marked a turn to deficit. The operating loss narrowed to KRW 10.7 billion in 2024, and in 2025 the company returned to operating profit of KRW 36.2 billion.

The operating margin fell from 3.4% in 2022 to -0.8% in 2023 and -0.5% in 2024 before recovering to 1.5% in 2025. Net profit attributable to controlling shareholders turned positive at KRW 24 billion in 2024, but swung back to a net loss of KRW 69.5 billion in 2025.

Net loss including non-controlling interests was KRW 41.8 billion in 2025, and the gap between the two measures reflects the share held by non-controlling interests. Operating cash flow was negative at KRW -39.7 billion in 2023 and KRW -89.9 billion in 2024, then turned to KRW 24.3 billion in 2025.

On a quarterly basis, Q4 2025 was the trough, with sales of KRW 619.5 billion, an operating loss of KRW 6.73 billion and a net loss attributable to controlling shareholders of KRW 115.5 billion.

Sales bottomed at KRW 534.8 billion in Q1 2026 and then rose to KRW 596.3 billion in Q2 and KRW 702.3 billion in Q3, two consecutive quarters of growth. Q3 2026 sales were still down 4.7% from a year earlier. Operating profit rose to KRW 6.62 billion in Q2 2026 and KRW 60 billion in Q3 2026.

Press reports tied the Q3 net profit of KRW 84.3 billion partly to an upfront payment from the Curevo sale to Eli Lilly announced in May 2026, so that quarter's bottom line carries a non-recurring element. Cumulative net loss attributable to controlling shareholders over the last four quarters was KRW 47 billion.

05

Industry analysis

Plasma-derived products and vaccines follow different demand patterns. For plasma products, collection capacity and center utilization drive output and unit costs, and the company attributed the narrowing of losses at its US subsidiary largely to higher utilization at its plasma collection centers.

Vaccines sell mostly in the flu season, which falls in Q3. Flu vaccine sales deferred from Q2 2026 were recognized in Q3, which widened quarter-to-quarter swings.

In the US immunoglobulin market, growth in patients with immunodeficiency disorders and expanded indications are cited as drivers, and ALYGLO is positioned as a growth product in that market. Licensing payments differ from product sales because they are largely one-time and add volatility to quarterly results.

In competition, the plasma business faces large pharmaceutical companies and overseas plasma operators. GC Holdings is classified in the same holding-company sector as Hanmi Science, but the business mix differs, so direct comparisons of results are limited.

Holding-company discounts across the sector depend on governance and the ownership structure of subsidiaries, so the stake held in GC Biopharma and the size of non-controlling interests matter here.

06

Outlook

The schedule items that the company and its subsidiary have described are ALYGLO sales and the recognition of licensing payments. GC Biopharma reported ALYGLO sales of about USD 51 million in the first half of 2026 and about USD 46 million in Q3.

Cumulative sales for the first three quarters came to about USD 97 million, roughly 64.7% of the annual sales target of USD 150 million. The same subsidiary said an upfront payment of KRW 46.8 billion under a Fabry disease therapy licensing agreement is scheduled to be recognized in Q4 results.

Press reports also cite the company expecting favorable results to continue in the second half. ABO Holdings is reported to have seen fixed-cost pressure ease as utilization at its seven plasma centers rose. The holding company's Q4 2026 results have not yet been published.

Preliminary Q4 2026 results are expected in early 2027, and the 2026 annual report must be filed by the end of March 2027. The next checkpoints are how the Q4 licensing payment flows into holding-level consolidated results and whether the operating margin holds near the Q3 level.

Licensing payments are low in recurrence and should be assessed separately from the sustainability of quarterly profits.

07

Valuation

PER
—
PBR
0.5×
ROE
-4.8%
EPS
-₩949
BPS
₩20,845
Dividend per share
₩300

Because cumulative net loss attributable to controlling shareholders over the last four quarters totaled KRW 47 billion, a price-to-earnings ratio on that basis cannot be calculated.

Net profit attributable to controlling shareholders turned positive in Q3 2026 at KRW 84.3 billion, but the large Q4 2025 loss remains inside the last-four-quarter window. The price-to-book ratio sits below 1, which means the shares trade at a discount to book value.

Total equity is KRW 1.76 trillion, but equity attributable to controlling shareholders is KRW 900.9 billion, so the non-controlling interest accounts for a large share of book value. When reading the price-to-book ratio, it matters whether the base is controlling-shareholder equity or total equity.

Dividends depend on dividends received from subsidiaries, and operating cash flow turned positive in 2025, which is a factual indicator of dividend capacity. The debt ratio rose from 82.6% in 2022 to 130.7% in 2025, a directional shift toward higher leverage relative to equity.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Continued recovery in operating profit

Operating profit moved from losses in 2023 and 2024 to KRW 36.2 billion in 2025. Quarterly operating profit then rose from KRW 3.06 billion in Q1 2026 to KRW 6.62 billion in Q2 and KRW 60 billion in Q3. The operating margin also moved back into positive territory in 2025 at 1.5%. Whether this trend holds after Q3 is the key checkpoint for the bullish case.

High-margin products and narrowing subsidiary losses

GC Biopharma reported ALYGLO sales of about USD 51 million in the first half of 2026 and about USD 46 million in Q3. ABO Holdings' higher plasma center utilization reduced fixed-cost pressure, according to the company.

Higher sales of high-margin products such as flu vaccines are cited as another reason for the improvement. Whether the fixed-cost relief persists is the next point to track.

Licensing payments and a turn in cash flow

If the KRW 46.8 billion upfront payment that GC Biopharma receives under the Fabry disease licensing deal is recognized in Q4, it affects consolidated results at the holding level. Operating cash flow shifted from KRW -89.9 billion in 2024 to KRW 24.3 billion in 2025.

Once the timing of this cash inflow is confirmed, it will help show how borrowing pressure and the debt ratio evolve.

09

Bear factors

Cumulative net losses and no meaningful PER

Net loss attributable to controlling shareholders was KRW 54.1 billion in 2023 and KRW 69.5 billion in 2025. Q4 2025 alone recorded a net loss attributable to controlling shareholders of KRW 115.5 billion. The last four quarters still total a KRW 47 billion net loss, so a PER on that basis cannot be calculated. Whether the Q3 2026 profit offsets this cumulative loss is the point that could weaken the bearish view.

Rising leverage and a thin controlling-shareholder equity base

The debt ratio rose from 82.6% in 2022 to 98.7% in 2023 and 130.7% in 2025. Total liabilities at the end of 2025 were KRW 2.31 trillion. Controlling-shareholder equity of KRW 900.9 billion is about half of total equity of KRW 1.76 trillion, so non-controlling interests make up a large share. If leverage rises further, the financial burden could increase.

Reliance on one-time gains and lower sales

Press reports tied the Q3 2026 net profit attributable to controlling shareholders of KRW 84.3 billion partly to the Curevo sale proceeds, which were a one-time item. Net profit attributable to controlling shareholders was KRW 1.55 billion in Q2 2026.

Q3 2026 sales of KRW 702.3 billion were up 17.8% from Q2 but down 4.7% from a year earlier. Without a recovery in the sales base to the year-earlier level, the profit improvement is difficult to treat as recurring.

10

Risk factors

Dependence on subsidiary results

The holding company does not manufacture products, so most sales and operating profit come from consolidated subsidiary results, mainly GC Biopharma. Factors such as losses at the US plasma centers or the seasonality of vaccines pass through to holding-level results quickly.

Subsidiary results are sometimes first released as preliminary figures that can change after external audit review.

Financial leverage and capital structure

The debt ratio was 130.7% at the end of 2025, with total liabilities of KRW 2.31 trillion. Operating cash flow was negative in both 2023 and 2024 and turned positive only in 2025, which is a single year of improvement. If the capital structure does not improve, funding conditions and dividend capacity could come under pressure.

Timing of licensing payments and one-time items

The Curevo sale proceeds and the KRW 46.8 billion Fabry licensing upfront payment can change quarterly profit significantly depending on when they are recognized. Such items do not recur, so they need to be separated when reading quarterly trends. Timing differences in deferred sales can also distort quarter-over-quarter growth rates.

11

What to watch next

  1. End of December 2026 (Q4 2026 close)

    Confirm whether the KRW 46.8 billion Fabry licensing upfront payment at GC Biopharma is recognized in Q4 results. The amount affects consolidated sales and net profit at the holding level.

  2. Early 2027 (Q4 2026 preliminary results)

    Check the direction of Q4 operating profit and profit attributable to controlling shareholders. How the cumulative four-quarter net loss of KRW 47 billion changes determines whether a profit-based PER can be calculated.

  3. By the end of March 2027 (2026 annual report filing)

    Review confirmed 2026 annual sales, operating margin, debt ratio and capital structure. These can then be compared with the 2025 figures in the disclosed results.

  4. By the end of March 2027 (ABO Holdings section of the 2026 annual report)

    Check whether higher utilization at ABO Holdings' plasma centers translated into lower fixed-cost burden over the full year. Whether the US plasma center losses keep narrowing is a key variable for the holding company's operating margin.

12

Overall view

The disclosed results show sales rising in 2024 and 2025 after the 2023 trough, and operating profit turning positive in 2025. Quarterly sales grew in both Q2 and Q3 of 2026, and Q3 operating profit widened to KRW 60 billion.

At the same time, cumulative net loss attributable to controlling shareholders over the last four quarters totals KRW 47 billion, and the debt ratio at the end of 2025 was 130.7%, higher than in 2022. Press reports tied the Q3 net profit partly to a subsidiary sale payment, so it is difficult to treat as recurring.

The price-to-book ratio sits below 1, but controlling-shareholder equity is about half of total equity, so the reading depends on the base used. Subsidiary ALYGLO sales, utilization at the US plasma centers and the timing of the Q4 licensing payment are the main variables for holding-level results.

The next checkpoints are the preliminary Q4 2026 results and the confirmed annual figures in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. moneypie.net
  2. kind.krx.co.kr
  3. kind.krx.co.kr
  4. kind.krx.co.kr
  5. kind.krx.co.kr
  6. newsprime.co.kr
  7. etoday.co.kr
  8. openbizdata.com
  9. msn.com
  10. leadeconomy.co.kr
  11. newsclaim.co.kr
  12. 100ssd.co.kr
  13. newsvalue.kr
  14. s-journal.co.kr
  15. vegannews.co.kr
  16. dealsite.co.kr
  17. news.bizwatch.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis